Bruker Expands Multiomics Portfolio with AI Powered Mass Spectrometry Solutions

Bruker Unveils Next-Generation Multiomics Mass Spectrometry Portfolio at ASMS 2026

Bruker showcased a product line of next-generation innovations in the field of mass spectrometry, which will pave the way for multiomics research, spanning from proteomics to metabolomics and beyond, as well as from environmental exposure sciences to industrial applications. New technologies announced include an enhanced timsMRMS mass spectrometer, the timsMRMS AIP family, the timsOmni family, and upgraded software that incorporates AI functionality, as well as hybrid workflows for 4D metabolomics.

Advancing Multiomics Research with AI-Driven Mass Spectrometry

Bruker's new portfolio enables deeper insights into molecular data in a single workflow – including advanced trapped ion mobility separation, ultra-high-resolution mass spectrometry and automated sample preparation with AI-driven proteoform sequencing. The company has released new AI-powered tools for the proteoform sequencing and post-translational modification analysis of its software: OmniScape 2027, ProteoScape 2027, and GlycoScape 2027.

In the automation process, Bruker leverages Integrated Protein Technologies to enhance the top-down proteomics workflows by simply preparing a single sample and the hybrid 4D Metabolomics platform.

According to Precedence Research, the Multiomics Market size was calculated at USD 3.24 billion in 2025 and is predicted to increase from USD 3.70 billion in 2026 to approximately USD 13.20 billion by 2035, expanding at a CAGR of 15.18% from 2026 to 2035, due to the escalating demand for fast and accurate disease diagnosis, discovery of new biomarkers, and the application of precision medicine.

Industry Impact and Outlook

Bruker's latest product releases highlight integrated multiomics tools that enhance the understanding of complex diseases through proteomics, metabolomics, AI-based analysis, and high-resolution mass spectrometry. These advancements aim to propel translational research, aid in identifying clinical biomarkers, support pharmaceutical development, and improve biotherapeutic characterization.

The innovations demonstrate the industry's direction towards AI-powered, high-throughput, automated multiomics systems that provide deeper biology insights at a lower cost. Future developments and advanced multiomics technologies will become an increasingly important aspect of personalized healthcare and the research arena for institutions, health care systems, and drug development firms.